Li X, Zhang J, Huang J, Ma A, Yang J, Li W, Wu Z, Yao C, Zhang Y, Yao W, Zhang B, Gao R.
J Am Coll Cardiol. 2013 Jun 6. doi:pii: S0735-1097(13)02178-5. 10.1016/j.jacc.2013.05.035. [Epub ahead of print
The purpose of this study was to assess the effects of Qili Qiangxin capsules in patients with chronic heart failure (CHF).
Qili Qiangxin capsules are a traditional Chinese medicine (TCM) that has been approved for the treatment of CHF, but the evidence supporting its efficacy remains unclear.
A total of 512 CHF patients were enrolled and randomly assigned to receive the placebo or Qili Qiangxin capsules in addition to their standard medications for the treatment of CHF. The primary endpoint was the reduction or percent change in the plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) level during 12 weeks of treatment.
At the 12-week follow-up, a significant reduction in the NT-proBNP level from baseline was observed in both groups, but the QiliQiangxin capsule group demonstrated a significantly greater reduction than the placebo group (p = 0.002); 47.95% of patients in the QiliQiangxin capsule group demonstrated reductions in NT-proBNP of at least 30% compared to 31.98% of patients in the placebo group (p < 0.001). Treatment with Qili Qiangxin capsules also demonstrated superior performance in comparison to the placebo with respect to New YorkHeart Association (NYHA) functional classification, left ventricular ejection fraction (LVEF), 6-minute walking distance (6MWD) and quality of life.
On a background of standard treatment, Qili Qiangxin capsules further reduced the levels of NT-proBNP. Together, our data suggest that Qili Qiangxin capsules could be used in combination therapy for CHF.